Published in Nat Rev Rheumatol on October 01, 2009
Inflammation-independent defective early B cell tolerance checkpoints in rheumatoid arthritis. Arthritis Rheum (2011) 1.62
Identification of a lysosomal pathway that modulates glucocorticoid signaling and the inflammatory response. Sci Signal (2011) 1.58
Cytokine-dependent but acquired immunity-independent arthritis caused by DNA escaped from degradation. Proc Natl Acad Sci U S A (2010) 1.50
The precursor of resolvin D series and aspirin-triggered resolvin D1 display anti-hyperalgesic properties in adjuvant-induced arthritis in rats. Br J Pharmacol (2011) 1.43
The changing face of rheumatoid arthritis: sustained remission for all? Nat Rev Immunol (2010) 1.10
Green tea polyphenol epigallocatechin 3-gallate in arthritis: progress and promise. Arthritis Res Ther (2010) 1.07
miR-346 controls release of TNF-α protein and stability of its mRNA in rheumatoid arthritis via tristetraprolin stabilization. PLoS One (2011) 1.06
The tumour-associated glycoprotein podoplanin is expressed in fibroblast-like synoviocytes of the hyperplastic synovial lining layer in rheumatoid arthritis. Arthritis Res Ther (2011) 1.05
Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial. Arthritis Res Ther (2010) 1.04
Development of a macromolecular prodrug for the treatment of inflammatory arthritis: mechanisms involved in arthrotropism and sustained therapeutic efficacy. Arthritis Res Ther (2010) 1.04
Treatment of experimental adjuvant arthritis with a novel folate receptor-targeted folic acid-aminopterin conjugate. Arthritis Res Ther (2011) 1.03
Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study. BMC Med (2012) 1.03
Factors influencing rheumatologists' prescription of biological treatment in rheumatoid arthritis: an interview study. Implement Sci (2014) 0.95
JNK-1 deficiency limits macrophage-mediated antigen-induced arthritis. Arthritis Rheum (2011) 0.94
Celastrol inhibits lipopolysaccharide-stimulated rheumatoid fibroblast-like synoviocyte invasion through suppression of TLR4/NF-κB-mediated matrix metalloproteinase-9 expression. PLoS One (2013) 0.93
Pharmacokinetic and biodistribution studies of N-(2-hydroxypropyl)methacrylamide copolymer-dexamethasone conjugates in adjuvant-induced arthritis rat model. Mol Pharm (2010) 0.92
Prevention of arthritis by locally synthesized recombinant antibody neutralizing complement component C5. PLoS One (2013) 0.90
Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis. MAbs (2012) 0.89
Lysosomal β-glucuronidase regulates Lyme and rheumatoid arthritis severity. J Clin Invest (2013) 0.87
Transport of anti-IL-6 antigen binding fragments into cartilage and the effects of injury. Arch Biochem Biophys (2013) 0.84
Murine analogues of etanercept and of F8-IL10 inhibit the progression of collagen-induced arthritis in the mouse. Arthritis Res Ther (2013) 0.84
The application of optical coherence tomography in musculoskeletal disease. Arthritis (2013) 0.84
S1P-targeted therapy for elderly rheumatoid arthritis patients with osteoporosis. Rheumatol Int (2010) 0.84
A metabolically-stabilized phosphonate analog of lysophosphatidic acid attenuates collagen-induced arthritis. PLoS One (2013) 0.84
Characterization of a novel and spontaneous mouse model of inflammatory arthritis. Arthritis Res Ther (2011) 0.83
The 20 year outcome and association between early treatment and mortality and disability in an inception cohort of patients with rheumatoid arthritis: Results from the Norfolk Arthritis Register. Arthritis Rheumatol (2017) 0.82
J-LEAPS peptide and LEAPS dendritic cell vaccines. Microb Biotechnol (2011) 0.81
Expression of K2P5.1 potassium channels on CD4+ T lymphocytes correlates with disease activity in rheumatoid arthritis patients. Arthritis Res Ther (2011) 0.81
Eupatilin ameliorates collagen induced arthritis. J Korean Med Sci (2015) 0.81
Pharmacokinetics, pharmacodynamics and toxicities of methotrexate in healthy and collagen-induced arthritic rats. Biopharm Drug Dispos (2013) 0.81
Non-HLA genes PTPN22, CDK6 and PADI4 are associated with specific autoantibodies in HLA-defined subgroups of rheumatoid arthritis. Arthritis Res Ther (2014) 0.80
Anti-inflammatory properties of prostaglandin E2: deletion of microsomal prostaglandin E synthase-1 exacerbates non-immune inflammatory arthritis in mice. Prostaglandins Leukot Essent Fatty Acids (2013) 0.80
Antibody-based delivery of IL4 to the neovasculature cures mice with arthritis. Proc Natl Acad Sci U S A (2014) 0.80
Accelerating translational research by clinically driven development of an informatics platform--a case study. PLoS One (2014) 0.80
Discovery of serum protein biomarkers in rheumatoid arthritis using MALDI-TOF-MS combined with magnetic beads. Clin Exp Med (2011) 0.79
Rheumatoid arthritis: can we achieve true drug-free remission in patients with RA? Nat Rev Rheumatol (2010) 0.79
Clinical trials in rheumatoid arthritis: a status report from the ClinicalTrials.gov website. Rheumatol Int (2011) 0.79
Psychophysiological responses to stress after stress management training in patients with rheumatoid arthritis. PLoS One (2011) 0.78
Significance of sex in achieving sustained remission in the consortium of rheumatology researchers of North America cohort of rheumatoid arthritis patients. Arthritis Care Res (Hoboken) (2012) 0.78
Safety of biologics in rheumatoid arthritis: data from randomized controlled trials and registries. Biologics (2015) 0.78
Novel method of monitoring trace cytokines and activated STAT molecules in the paws of arthritic mice using multiplex bead technology. BMC Immunol (2010) 0.77
Pharmacogenetics of rheumatoid arthritis: Potential targets from susceptibility genes and present therapies. Pharmgenomics Pers Med (2010) 0.77
SKLB023 blocks joint inflammation and cartilage destruction in arthritis models via suppression of nuclear factor-kappa B activation in macrophage. PLoS One (2013) 0.77
Association of MASP-2 levels and MASP2 gene polymorphisms with rheumatoid arthritis in patients and their relatives. PLoS One (2014) 0.77
Impact of remifentanil introduction on practice patterns in general anesthesia. J Anesth (2011) 0.77
RGD(F/S/V)-Dex: towards the development of novel, effective, and safe glucocorticoids. Drug Des Devel Ther (2016) 0.75
The Evaluation of the Therapeutic Efficacy and Side Effects of a Macromolecular Dexamethasone Prodrug in the Collagen-Induced Arthritis Mouse Model. Pharm Res (2015) 0.75
Pregnancy amelioration of arthritis in SKG mice corresponds with alterations in serum amyloid A3 levels. Am J Clin Exp Immunol (2012) 0.75
Periploca forrestii Saponin Ameliorates Murine CFA-Induced Arthritis by Suppressing Cytokine Production. Mediators Inflamm (2016) 0.75
Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants. Eur J Clin Pharmacol (2017) 0.75
Targeting cancer-related inflammation in the era of immunotherapy. Immunol Cell Biol (2017) 0.75
Biologics registers in RA: methodological aspects, current role and future applications. Nat Rev Rheumatol (2017) 0.75
Phytochemicals as potential antidotes for targeting NF-κB in rheumatoid arthritis. 3 Biotech (2017) 0.75
APL-1, an altered peptide ligand derived from heat-shock protein, alone or combined with methotrexate attenuates murine collagen-induced arthritis. Clin Exp Med (2016) 0.75
Meta-analysis of crowdsourced data compendia suggests pan-disease transcriptional signatures of autoimmunity. F1000Res (2016) 0.75
Regenerative medicine: Breaking Prometheus's curse for cartilage regeneration. Nat Rev Rheumatol (2017) 0.75
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum (1995) 15.00
A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med (1999) 11.62
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum (2006) 8.78
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum (2003) 8.50
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum (2005) 8.47
The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol (1983) 8.37
Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet (2004) 7.90
Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum (2004) 7.07
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis (2008) 6.97
Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet (1997) 6.71
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med (2005) 6.37
Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med (1995) 6.23
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum (2004) 6.22
The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med (1995) 5.83
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum (2006) 5.68
COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum (2002) 5.57
Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum (1998) 5.40
Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum (2006) 5.20
Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum (1993) 5.05
Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet (1999) 4.98
Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med (2003) 4.67
Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet (1989) 4.42
Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med (2001) 4.31
Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum (2005) 4.06
Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis (2007) 3.89
Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med (1996) 3.87
Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann Rheum Dis (2003) 3.43
Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med (1985) 3.37
Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis (2007) 3.31
Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum (1994) 3.15
Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med (1999) 3.10
Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis (2007) 2.75
Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis (2009) 2.44
Treatment of early rheumatoid arthritis with minocycline or placebo: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum (1997) 2.41
The health assessment questionnaire 1992: status and review. Arthritis Care Res (1992) 2.38
A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum (2007) 2.36
Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. Arthritis Rheum (1994) 2.32
Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum (2007) 2.31
Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum (2005) 2.27
IL-17 as a future therapeutic target for rheumatoid arthritis. Nat Rev Rheumatol (2009) 2.18
How to apply Larsen score in evaluating radiographs of rheumatoid arthritis in long-term studies. J Rheumatol (1995) 2.09
Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol (2009) 2.06
The clinical value of the Stanford Health Assessment Questionnaire Functional Disability Index in patients with rheumatoid arthritis. J Rheumatol (1988) 1.99
Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum (2007) 1.90
Comparison of azathioprine, methotrexate, and the combination of the two in the treatment of rheumatoid arthritis. A forty-eight-week controlled clinical trial with radiologic outcome assessment. Arthritis Rheum (1995) 1.82
A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum (2000) 1.79
Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2002) 1.79
Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum (2001) 1.68
Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum (1999) 1.57
Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. Arthritis Rheum (2005) 1.55
G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol (2009) 1.46
Rejuvenating the immune system in rheumatoid arthritis. Nat Rev Rheumatol (2009) 1.29
Regulatory T cells as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol (2009) 1.26
Promising bone-related therapeutic targets for rheumatoid arthritis. Nat Rev Rheumatol (2009) 1.25
Low dose prednisone therapy in rheumatoid arthritis: a double blind study. J Rheumatol (1983) 1.25
CD19: a promising B cell target for rheumatoid arthritis. Nat Rev Rheumatol (2009) 1.24
The antiinflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-5'-nucleotidase: findings in a study of ecto-5'-nucleotidase gene-deficient mice. Arthritis Rheum (2007) 1.22
Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe. Ann Rheum Dis (2009) 1.08
Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue. Ann Rheum Dis (2007) 1.05
Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis. A thirty-six-week, double-blind trial. Arthritis Rheum (1990) 1.04
Dendritic cells as targets for therapy in rheumatoid arthritis. Nat Rev Rheumatol (2009) 1.02
Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis. Clin Chim Acta (2005) 0.99
Toxicity of low dose methotrexate in rheumatoid arthritis. J Rheumatol Suppl (1985) 0.94
The hierarchy of quality-of-life assessment, the Health Assessment Questionnaire (HAQ), and issues mandating development of a toxicity index. Control Clin Trials (1991) 0.89
Methotrexate in rheumatoid arthritis: effects on disease activity in a multicenter prospective study. J Rheumatol (1991) 0.85
How to dose infliximab in rheumatoid arthritis: new data on a serious issue. Ann Rheum Dis (2009) 0.84
Challenging the therapeutic pyramid: a new look at treatment strategies for rheumatoid arthritis. J Rheumatol Suppl (1990) 0.83
Long term evaluation of radiographic disease progression in a subset of patients with rheumatoid arthritis treated with leflunomide beyond 2 years. Ann Rheum Dis (2004) 0.83
Inverting the therapeutic pyramid: observations and recommendations on new directions in rheumatoid arthritis therapy based on the author's experience. Semin Arthritis Rheum (1993) 0.82
Treatment of rheumatoid arthritis. New thoughts on the classic pyramid approach. Postgrad Med (1992) 0.77